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Abstract
The aim of this study was to describe the prevalence of adverse drug events 
(ADEs) and associated factors reported by users of medicines in Brazil. This 
was a cross-sectional population-based study conducted from September 2013 
to February 2014 with data from the Brazilian National Survey on Access, 
Use, and Promotion of Rational Use of Medicines (PNAUM). The study 
included all individuals that reported the use of medicines and identified, 
among them, all those reporting at least one problem with the medicine’s use. 
A descriptive analysis was performed to estimate ADE prevalence and 95% 
confidence intervals (95%CI) among the target variables. Crude and adjust-
ed prevalence ratios were calculated using Poisson regression to investigate 
factors associated with ADEs. Overall ADE prevalence in Brazil was 6.6% 
(95%CI: 5.89-7.41), and after multivariate analysis, higher prevalence was 
associated with female gender, residence in the Central and Northeast regions, 
consumption of more medicines, “bad” self-rated health, and self-medication. 
The drugs most frequently reported with ADEs were fluoxetine, diclofenac, 
and amitriptyline. The most frequent ADEs were somnolence, epigastric pain, 
and nausea. Most reported ADEs were mild, avoidable, and associated with 
medicines used frequently by the population. The study provided knowledge 
on the size of the problem with use of medicines in Brazil.
Drug Utilization; Drug-Related Side Effects and Adverse Reactions;
Pharmacovigilance; Health Surveys
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Introduction
Drugs play an essential role in the care of persons, whether for treatment, prevention, or diagnostic 
purposes; however, they also have the potential to cause unwanted events 1. The World Health Orga-
nization (WHO) defines adverse drug event (ADE) as “any negative or harmful occurrence that takes place 
during treatment, that may or may not be associated with a medicine” 2 (p. 26).
ADEs are considered a serious public health problem, since they not only account for increased 
morbidity and mortality in patients, but also lead to unnecessary expenditures by health systems. 
They thus have negative clinical, human, and economic impacts 3,4.
Factors contributing to ADEs in users of medicines include age 3,4,5, female gender 4,5, comorbidi-
ties 3,5, previous history of ADEs 6, polypharmacy 3,5,6, drug dose 5, nutritional status, environmental 
factors, and social habits 6. In addition to patient-related factors and factors inherent to the drug, 
resulting from its mechanism of action, lack of or insufficient treatment orientation, prescription 
of inappropriate medicines, lack of treatment adherence, and lack of treatment follow-up can lead 
to ADEs 4,6.
Numerous studies have investigated adverse events in the hospital setting 3,4,7. Cano & Rosenfeld 7 
conducted a systematic review on ADEs in hospital inpatients in 13 countries and found ADE rates 
ranging from 1.6% to 41.4%.
However, the data are still incipient on ADE prevalence in the community 6,8,9,10. A population-
based study in Cuba 8 found ADE prevalence of 22.6%. In Hong Kong (China) 9, ADE prevalence 
among persons that practiced self-medication was 6.4%, and in Italy, in the regions of Veneto 10 and 
Campania 11, interviews with pharmacists in community pharmacies found ADE prevalence rates of 
9.4% and 10.8%, respectively.
A population-based study by Arrais 6 in Fortaleza, Ceará State, Brazil, found ADE prevalence of 
8%. Prevalence was higher in women (9.7%), in the 50-64-year age bracket (14.9%), in individuals with 
chronic diseases (12%), among persons with lifetime report of ADEs (10%), and among those that 
rated their health as “bad”, and increased according to the number of medicines used.
According to the Brazilian National Notification System for Sanitary Surveillance (NOTIVISA) 
of the Brazilian Health Regulatory Agency (Anvisa; http://www.anvisa.gov.br/hotsite/notivisa/rela 
torios/index.htm, accessed on 20/Mar/2016), 103,887 adverse events were reported in Brazil from 
2006 to 2013, of which 38,730 were related to medicines.
ADEs in hospitals and the community compromise patient safety and have thus drawn increasing 
attention in the literature 12. However, the shortage of community-based studies on this topic hinders 
information on the true extent of drug-related morbidity and mortality and the extent to which ADEs 
affect patient safety in the broad scenario of modern consumer society 3. This lack of information 
hampers planning measures to implement a culture of patient safety among health professionals and 
to reduce the occurrence of ADEs 13.
In this context, the household survey component of the Brazilian National Survey on Access, Use, 
and Promotion of Rational Use of Medicines (PNAUM) 14, by the Brazilian Ministry of Health, allows 
calculating ADE prevalence and inferring the potential effects, thereby contributing to user safety in 
the community.
The current study aimed to estimate the prevalence and characteristics of adverse events report-
ed by users of medicines in Brazil, and to identify factors associated with their occurrence, com-
paring demographic and socioeconomic variables, self-rated health, number of medicines used, 
and self-medication.
Methods
This cross-sectional, population-based study of data from the PNAUM survey aimed to evaluate 
access to and rational use of medicines by the Brazilian population.
The PNAUM survey was conducted from September 2013 to February 2014 in a probabilistic 
sample of the Brazilian population, applying questionnaires. Household interviews were conducted 
by an outsourced company, trained by the PNAUM team, using tablets for the data collection. In the 
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case of persons under 15 years or with disabilities, the answers were given by their parents or guard-
ians. Further details on the sampling plan and sample size are available in the article on methodologi-
cal aspects of the PNAUM survey 14.
The questionnaire, consisting of 11 content sections and three forms with details on medicines, 
was developed and tested by the researchers involved in the PNAUM survey.
The target population for the current study included all persons who reported the use of at least 
one medicine, including drugs for continuous, occasional, or contraceptive use.
The “dependent” variable was defined as having consumed one or more medicines and having 
reported ADEs. Identification of users of medicines was based on the following questions:
For continuous-use medicines: “Have you used any medicine for (hypertension, diabetes, heart 
disease, high cholesterol, stroke, chronic lung disease, arthritis or rheumatism, depression, or another 
disease lasting more than six months)?” (yes, no). If yes, “Are you currently taking any of these medi-
cines?” (yes, no);
For medicines with occasional use: in addition to the above-mentioned medicines, “Have you used 
any other medicine in the last 15 days, for (infection, problems sleeping or for nerves, stomach or 
intestinal problems, fever, pain, flu, cold, allergic rhinitis, nausea, or vomiting)?” (yes, no);
For contraceptive use: “Are you using any contraceptive pill to avoid becoming pregnant?” (yes, 
no). “Do you use some injection to avoid becoming pregnant?” (yes, no).
Presence of ADEs among users of medicines was investigated with the following questions:
Does this medicine bother you or cause any problem? (yes, no). If yes, why? (This same question 
was used for continuous and occasional-use medicines);
Does the contraceptive cause any health problem for you? If yes, what problem(s)?
All persons who reported at least one health problem with the use of these medicines were classi-
fied as having suffered an ADE.
The “independent” variables were demographic, socioeconomic, self-rated health, number of 
medicines, and self-medication, analyzed as follows:
(a) Demographic: sex (female, male); age (0-9 years, 10-19 years, 20-39 years, 40-59 years, ≥ 60 years ; 
region (North, Northeast, Central, South, and Southeast).
(b) Socioeconomic: schooling (0-8 years, 9-11 years, and ≥ 12 years; ABEP Economic Classification 
(A/B, C, D/E), according to the Brazilian Economic Classification Criterion of the Brazilian Associa-
tion of Market Research Companies (ABEP; http://www.abep.org/).
(c) Health indicators: self-rated health status (very good, good, regular, bad, and very bad).
(d) Consumption of medicines: medicine(s) used; number of medicines (1, 2, 3-4, and 5 or more); form 
of consumption: self-medication (yes, no). Self-medication is defined here as the selection and use of 
medicines without supervision by a physician and/or dentist 15.
Medicines were listed and classified according to the Anatomical Therapeutic Chemical Clas-
sification System (ATC classification) 16. Description of the medicines used the following ATC levels: 
first (organ or system where the medicine acts), second (therapeutic subgroup), and fifth (drug).
ADE was defined by the WHO criterion 2. ADEs were classified according to the Adverse 
Reaction Terminology 17.
Statistical data analysis estimated the overall prevalence of ADEs in the study population and 
respective 95% confidence intervals (95%CI), according to the independent variables. The association 
between ADEs and target variables was investigated with the Pearson chi-square test, with signifi-
cance set at 5% (p < 0.05). Poisson regression was used to estimate crude and adjusted prevalence ratios 
(PR) and 95%CI. Variables with p < 0.20 in the test of association were included in the multivariate 
model, with significance set at 5% for maintaining variables in the model, using backward selection 
of variables. The schooling variable entered the first stage of the multivariate adjustment (together 
with the other variables with p < 20% in the crude analysis). From that point on, as determined by 
the backward selection method, the non- significant variables were removed. The variables that were 
removed include schooling, which at some moment failed to show significance at 5% to remain in the 
final model. The analyses used a set of appropriate svy commands for analysis of complex samples, 
which guaranteed the necessary weighting of the sampling design.
For the medicines, ADE frequencies were estimated according to organ or system (first ATC level), 
therapeutic subgroup (second ATC level), and drug (fifth ATC level), plus the respective 95%CI.
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All the analyses used Stata, version 13.0 (StataCorp LP, College Station, USA).
The PNAUM research project was approved by the Brazilian National Commission on Research 
Ethics (case review n. 18947013.6.0000.0008) and by the Institutional Review Board of the Fed-
eral University of Rio Grande do Sul (UFRGS), where the survey is coordinated, under case review 
n. 19997.
Results
Of the 41,433 participants in the PNAUM survey, 50.7% reported consuming medicines.
ADE prevalence was 6.6% overall, and was higher in females (7.8%), in the 20-39-year age bracket 
(8.2%), in the Central region (8.4%), with “bad” self-rated health (14.8%), with consumption of 5 or 
more medicines (14.7%), and with self-medication (7.8%) (Table 1).
Bivariate analysis showed a positive and statistically significant association between ADEs and 
the following variables: female sex; age; Northeast, Southeast, and Central regions; “fair”, “bad”, and 
“very bad” self-rated health; use of 2 or more medicines; and self-medication. There was no significant 
association between ADE prevalence and socioeconomic status (ABEP) or schooling (Table 2).
However, the multivariate analysis showed that only female sex (PR = 1.34; 95%CI: 1.05-1.72); 
the Central (PR = 1.54; 95%CI: 1.16-2.02) and Northeast regions (PR = 1.36; 95%CI: 1.04-1.79); “bad” 
self-rated health (PR = 1.90; 95%CI: 1.22-2.98); use of 2 (PR = 2.15; 95%CI: 1.59-2.91), 3-4 (PR = 3.57; 
95%CI: 2.54-5.01), and 5 or more medicines (PR = 6.30; 95%CI: 4.64-8.55); and self-medication (PR = 
1.21; 95%CI: 1.02-1.44) continued to show a positive and statistically significant association with 
ADEs (Table 2).
Of the 57,424 medicines consumed by the interviewees, 2,447 (4.2%) were related to the reported 
ADEs. Table 3 shows the therapeutic groups and subgroups most related to ADEs.
The groups or systems with the highest frequencies of ADEs were related to antineoplastic and 
immune-modulating agents (19.2%), followed by medicines for the genitourinary system and sex 
hormones (8.6%), and systemic-use anti-infectious agents (8%). The therapeutic subgroups with the 
highest frequencies of ADEs were sex hormones and modulators of the genital system (8.2%), followed 
by antiepileptics (7.9%) and anti-inflammatory and antirheumatic drugs (7.3%). The drugs with the 
highest frequencies of ADEs were fluoxetine (9.3%), diclofenac (9%), and amitriptyline (8.5%) (Table 4).
The organs or systems affected by ADEs involved mainly the gastrointestinal system (36.9%), fol-
lowed by psychiatric disorders (18.7%), general health status (13.1%), and the central and peripheral 
nervous systems (9%), with somnolence (12.5%), epigastric pain (10.5%), and nausea (6.8%) as the most 
frequently reported ADEs (Table 5).
Discussion
ADE prevalence in the overall Brazilian population was lower than in Cuba 8, Veneto 10 and Campania 11 
in Italy, and Fortaleza 6 in Brazil, and was higher than in persons that practiced self-medication in 
Hong Kong 9.
Nationwide studies to identify ADEs reported by the population are quite incipient in the inter-
national literature, which hinders comparison between countries. The Cuban study 8 found an ADE 
prevalence rate approximately four times greater than in the current study (22.6%). This result is 
probably influenced by the fact that subjects in Cuba reported events any time in life.
In general, and considering that every adverse drug reaction is an adverse drug event, most studies 
have been conducted in the hospital setting, related to admission for ADEs in the emergency depart-
ment or their occurrence during hospital stay 7,18,19. In the case of ADEs that occur during hospital 
stay, studies are limited to the drugs used in this setting. In the community, however, the consumption 
of medicines reflects the products’ wide availability on the pharmaceutical market, with countless 
pharmaceutical specialties, some of which have less than optimal intrinsic values and are even unnec-
essary or hazardous, which (associated with the pharmaceutical industry’s marketing) can result in 
induction or encouragement for inadequate use of medicines 6,20.
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Table 1
Prevalence of adverse drug events (ADEs) according to demographic and socioeconomic variables, self-rated health,  
use of medicines, and self-medication. Brazilian National Survey on Access, Use, and Promotion of Rational Use of  
Medicines (PNAUM), Brazil, 2014.
Variables ADEs (%) * 95%CI p-value **
Sex 0.000
Female 7.78 6.85-8.82
Male 4.53 3.61-5.68
Age (years) 0.000
0-9 3.31 2.34-4.64
10-19 7.79 5.93-10.16
20-39 8.17 7.07-9.42
40-59 7.13 6.18-8.23
≥ 60 4.88 3.95-6.01
Region 0.007
North 4.44 3.53-5.57
Northeast 7.15 6.11-8.35
Southeast 6.88 5.55-8.51
South 4.63 3.90-5.49
Central 8.40 6.88-10.22
ABEP classification *** 0.494
A/B 7.20 5.92-8.74
C 6.51 5.61-7.54
D/E 6.23 5.23-7.41
Schooling (years) 0.164
0-8 6.19 5.45-7.02
9-11 7.31 6.13-8.70
≥ 12 6.94 5.33-8.99
Self-rated health status 0.000
Very good 4.25 2.86-6.28
Good 5.73 4.83-6.79
Regular 9.60 8.32-10.98
Bad 14.81 12.02-18.13
Very bad 7.70 5.27-11.11
Medicines used 0.000
1 2.76 2.19-3.49
2 5.60 4.58-6.82
3-4 9.32 7.45-11.61
≥ 5 14.66 12.80-16.73
Self-mediciation 0.003
Yes 7.79 6.72-9.02
No 6.09 5.33-6.96
* Percentages adjusted by sampling weights and post-stratification by age and sex; 
** Chi-square statistic significant at 0.05; 
*** Variable for economic classification according to the Brazilian Economic Classification Criterion of the Brazilian 
Association of Market Research Companies (ABEP; http://www.abep.org/).
As for ADE prevalence in females, the same was found by Alonso Carbonell et al. 8 in Cuba and 
by Arrais 6 in Fortaleza. The factors that may explain this phenomenon include pharmacokinetic, 
pharmacodynamic, and body-weight when compared to men, besides hormonal factors 6,21. Women 
present more health problems, which are less serious on average, but they use health services more, 
Sousa LAO et al.6
Cad. Saúde Pública 2018; 34(4):e00040017
Table 2
Distribution of crude and adjusted prevalence ratios (PR) (Poisson regression) for adverse drug events (ADEs) and respective 95% confidence intervals 
(95%CI) according to study variables. Brazilian National Survey on Access, Use, and Promotion of Rational Use of Medicines (PNAUM), Brazil, 2014.
Variables Crude PR (95%CI) p-value * Adjusted PR (95%CI) p-value *
Sex 0.001 0.018
Female 1.72 (1.34-2.20) 1.34 (1.05-1.72)
Male 1.00 1.00
Age (years) 0.001 0.001
0-9 1.00 1.00
10-19 2.36 (1.59-3.50) 1.34 (0.73-2.45)
20-39 2.47 (1.74-3.49) 1.10 (0.61-1.99)
40-59 2.16 (1.50-3.11) 0.66 (0.36-1.22)
≥ 60 1.48 (1.01-2.14) 0.39 (0.20-0.72)
Region 0.001 0.000
North 1.00 1.00
Northeast 1.61 (1.22-2.12) 1.36 (1.04-1.79)
Southeast 1.55 (1.13-2.12) 1.21 (0.90-1.63)
South 1.04 (0.78-1.39) 0.82 (0.62-1.09)
Central 1.89 (1.40-2.56) 1.54 (1.16-2.02)
ABEP classification ** 0.499
A/B 1.16 (0.90-1.48)
C 1.04 (0.85-1.29)
D/E 1.00
Schooling (years) 0.139
0-8 1.00
9-11 1.18 (0.99-1.41)
≥ 12 1.12 (0.87-1.45)
Self-rated health status 0.001 0.003
Very good 1.00 1.00
Good 1.35 (0.90-2.01) 1.15 (0.79-1.68)
Regular 2.26 (1.52-3.35) 1.47 (0.98-2.20)
Bad 3.48 (2.23-5.44) 1.90 (1.22-2.98)
Very bad 1.81 (1.03-3.17) 0.90 (0.50-1.62)
Medicines used 0.001 0.001
1 1.00 1.00
2 2.02 (1.51-2.70) 2.15 (1.59-2.91)
3-4 3.37 (2.52-4.51) 3.57 (2.54-5.01)
≥ 5 5.30 (4.15-6.80) 6.30 (4.64-8.55)
Self-mediciation 0.003 0.006
Yes 1.28 (1.09-1.50) 1.21 (1.02-1.44)
No 1.00 1.00
* Level of significance (p < 0.05); 
** Variable for economic classification according to the Brazilian Economic Classification Criterion of the Brazilian Association of Market Research 
Companies (ABEP; http://www.abep.org/).
have more appointments and tests, obtain more diagnoses and medical prescriptions, and thus con-
sume more medicines, prescribed or not 15,22,23. Another factor that may have contributed to this 
gender difference was the fact that ADEs were also reported by users of contraceptives in the study.
As for age bracket, we expected to find higher ADE prevalence at the extremes of age (children and 
elderly), since according to the literature these are the groups most predisposed to ADEs 24. However, 
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Table 3
Frequency of adverse drug events (ADEs) and respective 95% confidence intervals (95%CI) according to the organ or system and therapeutic subgroup 
related to the drug reported as causing the problem. Brazilian National Survey on Access, Use, and Promotion of Rational Use of Medicines (PNAUM),  
Brazil, 2014.
Variables % * 95%CI
Principal anatomical group
Antineoplastic and immune-modulating agents 19.25 12.34-28.76
Genitourinary system and sex hormones 8.63 7.07-10.50
Anti-infectious agents for systemic use 8.05 5.82-1.03
Musculoskeletal system 7.09 5.84-8.60
Dermatological products 6.89 3.94-11.78
Blood and hematopoietic organs 6.65 4.10-10.59
Respiratory system 5.80 4.26-7.84
Anti-parasitic products, insecticides, and repellents 5.72 2.26-13.72
Nervous system 5.55 4.63-6.63
Systemic hormonal preparations except sex hormones and insulins 5.54 3.98-7.65
Herbal remedies, supplements, homeopathy, foods 5.15 3.80-6.95
Alimentary tract and metabolism 4.37 3.66-5.20
Cardiovascular system 4.02 3.28-4.93
Sense organs 3.66 1.95-6.77
Unknown 1.70 0.20-12.85
Various 0.79 0.10-5.83
Therapeutic subgroup
G03 Sex hormones and modulators of the genital system 8.24 6.64-10.19
N03 Anti-epileptics 7.89 5.24-11.73
M01 Anti-inflammatory and Antirheumatic products 7.33 5.78-9.26
J01 Antibacterial drugs for systemic use 7.07 5.01-9.88
R01 Nasal preparations 7.06 3.92-12.41
N06 Psychoanaleptics 7.04 5.30-9.29
M03 Muscle relaxants 6.96 5.05-9.53
R06 Antihistamines for systemic use 6.95 3.92-12.04
H02 Corticosteroids for systemic use 6.81 4.41-10.36
R03 Drugs for obstructive airway diseases 6.78 4.38-10.34
C01 Cardiac therapy 6.47 3.76-10.93
N05 Psycholeptics 5.23 3.30-8.19
A02 Drugs for acid related disorders 5.15 3.98-6.64
A10 Drugs used in diabetes 4.98 3.77-6.56
N02 Analgesics 4.79 3.84-5.96
H03 Thyroid therapy 4.76 2.92-7.68
C03 Diuretics 4.56 3.32-6.24
C07 Beta blocking agents 4.47 2.83-7.01
R05 Cough and cold preparations 3.08 1.88-4.99
C10 Lipid modifying agents 2.92 2.08-4.10
A11 Vitamins 2.57 1.58-4.14
C08 Calcium channel blockers 2.41 1.54-3.76
A03 Drugs for functional gastrointestinal disorders 2.21 1.27-3.81
* Analyzed with weight and complex plan.
we observed the highest ADE prevalence in young people and young adults. This result may be explained in part by the ADEs 
reported by contraceptive users, or by difficulties by patients and/or caregivers in identifying ADEs; aggravated by lack of 
information, this may have influenced the result and contributed to minimizing ADE prevalence in children and the elderly 21,25.
Sousa LAO et al.8
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Table 4
Frequency of adverse drug events (ADEs) and respective 95% confidence intervals (95%CI), according to drug reported as 
cause of problem. Brazilian National Survey on Access, Use, and Promotion of Rational Use of Medicines (PNAUM),  
Brazil, 2014.
Drugs % * 95%CI
Fluoxetine 9.32 5.53-15.29
Diclofenac 9.05 5.12-15.50
Amitriptyline 8.54 5.45-13.13
Caffeine; carisoprodol; diclofenac; paracetamol 8.28 5.40-12.48
Prednisone 8.24 4.75-13.92
Nimesulide 8.04 4.60-13.70
Ethinylestradiol; levonorgestrel 7.60 5.68-10.10
Cyproterone; ethinylestradiol 7.29 4.25-12.24
Clonazepam 7.06 4.18-11.66
Amoxicillin 6.48 3.77-10.91
Metformin 6.41 4.74-8.62
Ibuprofen 6.27 4.16-9.34
Captopril 6.19 4.10-9.23
Dipyrone 5.26 3.85-7.15
Supplements 5.14 2.99-8.68
Omeprazole 4.99 3.61-6.85
Caffeine; dipyrone; orphenadrine 4.86 2.92-8.00
Levothyroxine 4.85 2.96-7.85
Hydrochlorothiazide 4.63 3.13-6.80
Enalapril 4.51 2.81-7.16
Caffeine; dipyrone; isometheptene 4.22 2.37-7.39
Ethinylestradiol; gestoden 3.89 2.15-6.92
Paracetamol 3.43 2.42-4.84
Atenolol 3.38 2.03-5.57
Acetyl salicylic acid 3.31 2.14-5.07
Simvastatin 2.60 1.76-3.83
Losartan 2.47 1.78-3.42
Amlodipine 2.26 1.30-3.90
Unknown 6.06 4.11-8.85
* Analyzed with weight and complex plan.
As for the higher association between consumption of medicines and ADEs in residents of the 
Northeast and Central regions of Brazil, the lack of similar studies prevents a more detailed explana-
tion. However, this result may be influenced by difficulties in access to health services and the need 
to relieve minor symptoms with self-medication 15,22,26, which involves some of the most widely used 
medicines in this study 6,15,23,27. Self-medication is practiced in all regions of Brazil. Self-medication 
rates in the North (17.8%), Northeast (23.5%), and Central (19.2%) were higher than the national rate 
(16.1%) 15.
Polypharmacy was significantly associated with ADEs, corroborating findings in the literature 6,24. 
ADEs increase significantly with the number of drugs used by the patient and the treatment com-
plexity, since polypharmacy appears as a potential risk factor for drug-drug interactions, medication 
errors, and inadequate use of medicines, potentially resulting in hospitalization, and in severe cases, 
death 28,29. This risk can be minimized by greater control of polypharmacy by health professionals, 
adequate prescription, patient-adjusted doses, and effective pharmacotherapeutic follow-up 30.
As for self-rated health status, patients with “bad” self-rated health reported the most ADEs, 
similar to the study by Arrais 6. This generally occurs because these patients are more likely to seek 
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Table 5
Characteristics of adverse drug events (ADEs) according to organ/system affected and reported events among 
interviewees that consumed medicines. Brazilian National Survey on Access, Use, and Promotion of Rational Use  
of Medicines (PNAUM), Brazil, 2014.
Variables % 95%CI
Organ/System affected
Disorders of the gastrointestinal system 36.9 32.6-41.3
Psychiatric disorders 18.7 14.6-23.7
Disorders of overall health status 13.1 10.6-16.1
Disorders of the central and peripheral nervous systems 9.0 6.8-11.8
Disorders of the urinary system 4.1 2.7-6.1
Disorders of the respiratory system 3.8 2.5-5.7
Disorders of cardiac rate and rhythm 3.5 2.3-5.3
Disorders of the cardiovascular system 1.4 0.7-2.7
Disorders of the female reproductive system 1.4 0.7-2.7
Disorders of the liver and gallbladder 1.3 0.7-2.5
Conditions of the skin and related disorders 1.1 0.6-2.1
Disorders of the sense organs 0.9 0.5-1.8
Other problems, not health 4.8 3.5-6.6
ADE reported
Somnolence 12.5 9.6-16.0
Epigastric pain 10.5 8.3-13.3
Nausea 6.8 5.2-8.9
Gastric discomfort 4.6 3.1-6.7
Dizziness 4.4 2.8-6.7
Gastric hyperacidity 3.5 2.1-5.8
Tachycardia 3.2 2.0-5.0
Weight gain 3.4 2.3-5.0
Polyuria 3.4 2.1-5.3
Headache 3.1 1.9-4.8
Cough 3.0 2.0-4.5
Diarrhea 2.4 1.6-3.6
Weakness 2.3 1.2-4.2
Malaise 2.2 1.3-3.7
Dry mouth 1.5 0.7-3.3
Edema 1.2 0.6-2.3
Pain 1.0 0.5-1.9
Tremor 0.9 0.5-1.5
Vomiting 0.8 0.4-1.6
Decreased blood pressure 0.8 0.4-1.5
Insomnia 0.8 0.5-1.5
Not classified 2.6 1.8-3.9
Other * 25.2 21.6-29.2
* Events that occurred at rates less than 0.8%.
medical care and consume more medicines, prescribed or not, in the attempt to solve their health 
problems 6,31.
Patients in this study that self-medicated showed higher ADE prevalence, corroborating the stud-
ies by Lam et al. 9 in Hong Kong, Arrais 6 in Fortaleza, and Yu et al. 32 in Korea Republic.
Self-medication is common not only in Brazil 15, but worldwide, and it involves economic, politi-
cal, and cultural factors 26. Self-medication may or may not benefit the individual: when used rational-
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ly, it can mean a savings for the patient due to ease in acquiring the medicine and possible resolution 
of the health problem, and for health services, due to the reduction in demand for care and hospital 
expenses. But if used irrationally, self-medication can delay the correct diagnosis of a disease, mask 
symptoms, increase antimicrobial resistance, and harm the individual’s health through the appear-
ance of ADEs such as medication errors, adverse reactions, and intoxication 33.
Education and awareness-raising for health professionals and the general population are thus 
necessary, focusing on the rational use of medicines, the development of public policies fostering 
improved access to health services, more intense regulation of abusive advertising and irregular sales 
of over-the-counter drugs 34, and especially effective action by pharmacists in community pharmacies 
to minimize harm to the population’s health due to self-medication 35.
ADEs were proportionally more frequent with less consumed drugs, but with greater potential for 
adverse reactions or drug-drug interactions, as with fluoxetine and amitriptyline, which should thus 
be used under strict supervision 36. But ADEs also appeared with drugs that are frequently used in 
Brazil, with or without prescriptions, such as diclofenac, fixed-dose caffeine + carisoprodol + diclof-
enac + paracetamol, prednisone, and nimesulide 6,15,23,27.
In the case of non-steroidal anti-inflammatory drugs (NSAIDs), there are important restrictions 
on use in the elderly, with the possibility of gastrointestinal, renal, and cardiovascular risks and 
interaction with other drugs frequently used in primary care (paracetamol, some anti-hypertensives, 
antidepressants, and selective serotonin reuptake inhibitors) 37.
Adverse events associated with oral contraceptives featured levonorgestrel associated with ethi-
nylestradiol, and ciproterone+ethinylestradiol, the most widely consumed oral contraceptives on the 
Brazilian pharmaceutical market 38. Risks associated with contraceptives have been reported in the 
literature and range from mild and common, like nausea, headache, breast pain, anxiety, and irritabil-
ity, to rare and severe, like thromboembolism and stroke, as an important cause of treatment switch 
and dropout 39.
ADEs reported in the community are generally mild 6,8 and considered preventable, since they 
usually do not require specific treatment or suspension of the drug 24,40. However, the fact that they 
are mild does not minimize their importance, since they can interfere in quality of life, cause discom-
fort and malaise, and reduce treatment adherence and patients’ trust in their physicians 3. They may 
also aggravate the patient’s clinical status, causing new adverse events if the patient fails to use other 
medicines to minimize or relieve the discomfort generated by the offending drug, triggering the so-
called cascade effect 6.
Analyzing the three most frequently reported ADEs (somnolence, epigastric pain, and nausea), in 
some treatments these are already expected and do not greatly compromise the individual’s quality of 
life, thus rarely resulting in hospitalization, but causing patient discomfort and potentially leading to 
other consequences (cited above) such as treatment dropout.
The study’s limitations include the population’s lack of knowledge for identifying the association 
between use of the medicine and the adverse event, probably due to the difficulty in differentiating 
between the problem caused by the drug and complications or evolution of the disease itself; the recall 
period used to investigate use of the medicine and appearance of the ADE; failure to detect more seri-
ous events leading to the treatment’s interruption; inclusion of contraceptives in the analysis, favoring 
the inclusion of more females than males; and the fact that the question on adverse effects was worded 
in the context of treatment adherence and not as an objective formulation for evaluation.
Although the questions on ADEs considered the time of use of the medicines, one cannot state 
for certain that the ADE actually occurred during this period, or that the problem was related to the 
reported drug, but at a different moment. In addition, since no investigation was performed to deter-
mine the correlation between use of the medicine and the appearance of ADEs, one cannot state with 
certainty whether the events are related to the drugs reported as causing the problems or that other 
factors are influencing the outcome. 
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Conclusion
The current study allowed identifying ADEs and their determinant factors in Brazil. The adverse 
events were mainly mild, avoidable, and associated with medicines frequently used by the population. 
This information will allow developing measures for the prevention and reduction of ADEs, thereby 
contributing to both patient safety and reduction in healthcare costs resulting from damage caused 
by the use of medicines, especially in primary care.
However, the scarcity of nationwide studies on this topic and the fact that Brazil is one of the 
world’s 10 leading pharmaceutical markets 41 highlight the need to strengthen policies to promote 
the rational use of medicines.
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Resumo
O presente trabalho tem como objetivo descrever a 
prevalência e fatores associados a eventos adver-
sos a medicamentos (EAM) referidos por usuários 
de medicamentos no Brasil. Trata-se de um estu-
do transversal de base populacional, realizado no 
período de setembro de 2013 a fevereiro de 2014, 
com dados coletados na Pesquisa Nacional so-
bre Acesso, Utilização e Promoção do Uso 
Racional de Medicamentos (PNAUM). Foram 
consideradas todas as pessoas que referiram o uso 
de medicamentos; entre elas, foram identificadas 
as que referiram pelo menos um problema com o 
uso do medicamento. Realizou-se uma análise des-
critiva para estimar a prevalência e os intervalos 
de 95% de confiança (IC95%) de EAM entre as 
variáveis estudadas, e foram calculadas as razões 
de prevalência bruta e ajustada, pela regressão 
de Poisson, na investigação dos fatores associados 
aos EAM. A prevalência de EAM no Brasil foi de 
6,6% (IC95%: 5,89-7,41), sendo maior e estatisti-
camente significante após a realização da análise 
multivariada, entre pessoas do sexo feminino; re-
sidentes nas regiões Centro-oeste e Nordeste; que 
consumiam maior número de medicamentos; que 
percebiam seu estado de saúde como “ruim”; e que 
se automedicavam. Os EAM foram mais relatados 
para os medicamentos fluoxetina, diclofenaco e 
amitriptilina. Os EAM mais referidos pelos entre-
vistados foram sonolência, dor epigástrica e náu-
seas. Os EAM mais referidos pelos entrevistados 
foram de natureza leve, considerados evitáveis e 
estiveram associados a medicamentos de uso fre-
quente pela população. Em razão desse estudo, foi 
possível conhecer a dimensão do problema ocasio-
nado pelo uso de medicamentos no Brasil.
Uso de Medicamentos; Efeitos Colaterais e 
Reações Adversas Relacionados a Medicamentos; 
Farmacovigilância; Inquéritos Epidemiológicos
Resumen
El presente trabajo tiene como objetivo describir 
la prevalencia y factores asociados a eventos ad-
versos con medicamentos (EAM), informados por 
usuarios de medicamentos en Brasil. Se trata de 
un estudio transversal de base poblacional, rea-
lizado durante el período de septiembre de 2013 
a febrero de 2014, con datos recogidos en la En-
cuesta Nacional sobre el Acceso, Utilización 
y Promoción del Uso Racional de Medica-
mentos en Brasil (PNAUM). Se consideraron a 
todas las personas que informaron del uso de me-
dicamentos; entre ellas, se identificaron a las que 
informaron de por lo menos un problema con el 
uso del medicamento. Se realizó un análisis des-
criptivo para estimar la prevalencia y los interva-
los de confianza a 95% (IC95%) de EAM entre las 
variables estudiadas, y se calcularon las razones de 
prevalencia bruta y ajustada, por la regresión de 
Poisson, en la investigación de los factores asocia-
dos a los EAM. La prevalencia de EAM en Brasil 
fue de un 6,6% (IC95%: 5,89-7,41), siendo mayor 
y estadísticamente significante tras la realización 
del análisis multivariado, entre personas del sexo 
femenino; residentes en las regiones Centro-Oes-
te y Nordeste; que consumían un mayor número 
de medicamentos; que percibían su estado de sa-
lud como “malo”; y que se automedicaban. Se in-
formaron de más EAM en medicamentos como: 
fluoxetina, diclofenaco y amitriptilina. Los EAM 
más referidos por los entrevistados fueron som-
nolencia, dolor epigástrico y náuseas. Los EAM 
más referidos por los entrevistados fueron de na-
turaleza leve, considerados evitables y estuvieron 
asociados a medicamentos de uso frecuente por la 
población. Con motivo de este estudio, fue posible 
conocer la dimensión del problema ocasionado por 
el uso de medicamentos en Brasil.
Utilización de Medicamentos; Efectos Colaterales 
y Reacciones Adversas Relacionados con 
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